Robert P. Myers, Samuel S. Lee – 13 February 2012 – Myocardial contractility in cirrhosis is impaired, particularly under stressful situations, in a phenomenon termed cirrhotic cardiomyopathy. Impairment of the cardiac β‐adrenergic receptor and its signaling function appears to be involved in the pathogenesis of this disorder. Additional mechanisms that may have a role include alterations in the physicochemical properties of the cardiomyocyte plasma membrane and abnormalities in circulating humoral factors, such as nitric oxide, carbon monoxide, and catecholamines.

Arthur J. McCullough – 13 February 2012

Andre M. De Wolf – 13 February 2012

William T. Merritt – 13 February 2012

Susanna Naggie, Anu Osinusi, Antonios Katsounas, Richard Lempicki, Eva Herrmann, Alexander J. Thompson, Paul J. Clark, Keyur Patel, Andrew J. Muir, John G. McHutchison, Joerg F. Schlaak, Martin Trippler, Bhavana Shivakumar, Henry Masur, Michael A. Polis, Shyam Kottilil – 13 February 2012 – Recent studies have shown that a single‐nucleotide polymorphism upstream of the interleukin‐28B (IL28B) gene plays a major role in predicting therapeutic response in hepatitis C virus (HCV)‐infected patients treated with pegylated interferon (PEG‐IFN)/ribavirin.

Deborah L. Diamond, Alexei L. Krasnoselsky, Kristin E. Burnum, Matthew E. Monroe, Bobbie‐Jo Webb‐Robertson, Jason E. McDermott, Matthew M. Yeh, Jose Felipe Golib Dzib, Nathan Susnow, Susan Strom, Sean C. Proll, Sarah E. Belisle, David E. Purdy, Angela L. Rasmussen, Kathie‐Anne Walters, Jon M. Jacobs, Marina A. Gritsenko, David G. Camp, Renuka Bhattacharya, James D. Perkins, Robert L. Carithers, Iris W. Liou, Anne M. Larson, Arndt Benecke, Katrina M. Waters, Richard D. Smith, Michael G.

Kenneth Baker, Stanley A. Nasraway – 13 February 2012

Willis C. Maddrey – 13 February 2012

Norah A. Terrault, Michelle E. Roland, Thomas Schiano, Lorna Dove, Michael T. Wong, Fred Poordad, Margaret V. Ragni, Burc Barin, David Simon, Kim M. Olthoff, Lynt Johnson, Valentina Stosor, Dushyantha Jayaweera, John Fung, Kenneth E. Sherman, Aruna Subramanian, J. Michael Millis, Douglas Slakey, Carl L. Berg, Laurie Carlson, Linda Ferrell, Donald M. Stablein, Jonah Odim, Lawrence Fox, Peter G.

J.M. Aguado, E. Varo, P. Usetti, J.C. Pozo, A. Moreno, M. Catalán, O. Len, M. Blanes, A. Solé, P. Muñoz, M. Montejo, the TOSCANA Study Group – 12 February 2012 – The aim of this study was the evaluation of the safety of anidulafungin in adult solid organ transplantation (SOT) recipients. During the study period (14 months), we included all consecutive SOT recipients from 14 centers who received anidulafungin for at least 48 hours for the treatment of invasive fungal infections (IFIs) or as prophylaxis. Relevant clinical and analytical information on clinical charts was reviewed.